Prognose

Das durchschnittliche Kursziel der Analysten beträgt +12,08€(+230,96%). Der Median liegt bei +11,03€(+202,19%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the “Board”) reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and.» Mehr auf businesswire.com
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.» Mehr auf benzinga.com
Bluebird bio receives non-binding bid for up to $110.5 million
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.» Mehr auf reuters.com

Im letzten Quartal hatte Bluebird Bio Aktie einen Umsatz von 37,02 Mio€ und ein Nettoeinkommen von −27,59 Mio€